OVERVIEW OF THE DREAMM-2 STUDY

PURPOSE

EVALUATION OF THE SAFETY AND EFFICACY OF BLENREP

Inclusion Criteria

- Eligible patients were required to:
  - have relapsed or refractory multiple myeloma
  - have previously received ≥3 prior therapies (including an anti-CD38 monoclonal antibody)
  - be refractory to an immunomodulatory agent and a proteasome inhibitor
  - have measurable disease according to IMWG criteria
  (Not an all inclusive list. See ClinicalTrials.gov Identifier: NCT03525678)

Exclusion Criteria

- Patients were excluded from the study if they had:
  - corneal epithelial disease at baseline; exception: mild punctate keratopathy
  (Not an all inclusive list. See ClinicalTrials.gov Identifier: NCT03525678)

Design

- Open-label, multicenter
- Two treatment groups received Blenrep until disease progression or unacceptable toxicity
  - 2.5 mg/kg intravenously once every 3 weeks (recommended dosage) OR
  - 3.4 mg/kg intravenously once every 3 weeks (1.4x the recommended dose)

Efficacy Outcome Measure

- Overall response rate based on the IMWG Uniform Response Criteria for Multiple Myeloma

Study Population

- 218 patients received Blenrep (safety population)
- 53% were exposed for ≥6 months
- 24% were exposed for ≥6 months
- Baseline demographics of 2.5 mg/kg treatment group (n=97)
  - Median age: 65 years (range: 39-85)
  - 74% White
  - 53% male
  - 16% Black
  - Median number of prior lines of therapy: 7 (range: 3-21)

- 77% were ISS Stage II or III
- 16% had an ECOG performance status of 2
- 87% received prior ASCT
- 27% had high-risk cytogenetic factors present

ASCT: Autologous Stem Cell Transplantation; ECOG: Eastern Cooperative Oncology Group; IMWG: International Myeloma Working Group; ISS: International Staging System